FOLH1 and posterior cortical atrophy: The 177Lu-PSMA-617 therapy has shown promising results in the therapy of PSMA-positive castration-resistant PCa while PSMA-targeting ligands (such as 8F-PSMA-1007 or 68Ga-PSMA-617) are being studied for PCa imaging using PET/CT [105,106].